Ophthalmologists across the United States can now order the Lucentis 0.5 mg prefilled syringe (PFS). The PFS is a new method of administering Lucentis to treat people with wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), and myopic choroidal neovascularization (CNV).
Genentech announced the Lucentis PFS was approved by the FDA on October 14, 2016, offering a ready-to-use option to deliver treatment. This is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat three different eye diseases.
The Lucentis PFS allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration.
Lucentis 0.5 mg was recently FDA-approved as the first anti-VEGF medicine to treat patients with myopic CNV.